Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- VC Catalys Pacific Kicks Off in Japan in Partnership with Chugai, Eisai, Takeda, and More
June 18, 2019
- Daiichi Sankyo Espha Rolls Out AstraZeneca’s 3 Cancer AGs; Gx Onslaught for Lonasen, Urief
June 14, 2019
- Sumitomo Dainippon Tweaks Healios Cell Therapy Deal, Now Leads Japan Trials
June 14, 2019
- Nesp Biosame Priced at 62.8-69.2% of Originator
June 14, 2019
- Japanese Drug Makers Beefing Up China Biz amid Regulatory Tailwind
June 14, 2019
- Takeda to Propose Adding Shire Integration as Performance Objective for Execs’ Stock Compensation
June 14, 2019
- Shionogi Snaps Up Osaka Biotech after Hitting Joint Study Goals
June 14, 2019
- Takeda Founding Family Member Presses for Claw-Back Clause
June 13, 2019
- Growth of Japan Pharma Business Counts on Partnership with Foreign Biotechs: IQVIA Director
June 13, 2019
- Rakuten Medical Could File Photoimmunotherapy for Head and Neck Cancer in 2022; COO Says More Indications Eyed
June 12, 2019
- Taiho Sets Up Venture Capital to Spur Innovation in Japan
June 11, 2019
- Novartis’ Xolair Effective in Severe Cedar Pollen Allergy: Japan PIII
June 11, 2019
- JCR to Launch Japan PI/II for Temcell in Neonatal Hypoxic-Ischemic Encephalopathy
June 11, 2019
- Japan Ethical Drug Sales Surge 5.1% in April: Crecon
June 11, 2019
- Japan Ethical Drug Sales Shrivel, but Many Beat Conservative Guidance
June 11, 2019
- Amicus to Enroll PIII Study for Pompe Therapy AT-GAA by Year-End: COO
June 10, 2019
- Napabucasin PIII Colorectal Cancer Trial to Continue: Sumitomo Dainippon
June 10, 2019
- Keytruda Tops Drug Sales Ranking in May: Encise Snapshot
June 10, 2019
- Pfizer Keeps Diverse Portfolio Strategy amid Sluggish Bavencio, Oncology Chief Says I/O Just One Area of Cancer Care
June 10, 2019
- Oral MDS Treatment ASTX727 Equivalent to IV Dacogen in PIII Study: Otsuka
June 10, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…